Josep Carreras Leukaemia Research Institute is an International Research Institute whose mission is to investigate fundamental, epidemiological, preventive, clinical and translational aspects of leukemia, lymphoma, and other hematologic malignancies.
Subscribe to rss feed
For a long time, cancer genetics and epigenetics researchers have been focusing on alterations in genes and proteins to understand what makes a cell turn cancerous and become malignant. In the nucleus of the cell, there is ...
Jan 25, 2023
0
4
Researchers of the Hospital Universitario 12 de Octubre in Madrid and the Josep Carreras Leukaemia Research Institute in Barcelona have developed a cell therapy for a type of leukemia which currently has very few treatment ...
Jan 16, 2023
0
23
In the early 1980s, the first changes in DNA related to a chemical modification called methylation were discovered, followed by the discovery in the mid-1990s of the first tumor suppressor genes inactivated by these modifications ...
Dec 22, 2022
0
2
Researchers from the Epigenetics and Immune Disease Lab at the Josep Carreras Leukaemia Research Institute have recently shown that vitamin C improves the immunogenic properties of dendritic cells in vitro.
Nov 2, 2022
0
5
All human tumors originating from various tissues share a series of properties that define them, including the ability to prevent cell death. Instead, healthy organs induce programmed cell death or apoptosis to balance their ...
Aug 1, 2022
0
29
An international research team coordinated by Dr. Oscar Molina and Dr. Pablo Menéndez, from the Josep Carreras Leukaemia Research Institute, identifies chromosomal abnormalities associated with relapse in a frequent subset ...
Jul 7, 2022
0
16
Researchers from the Cancer Epigenetics group led by Dr. Manel Esteller at the Josep Carreras Leukaemia Research Institute and Dr. Aurora Pujol, from the Bellvitge Biomedical Research Institute (IDIBELL), have identified ...
Jun 27, 2022
0
26
A team of researchers led by Dr. Sandra Castillo and Dr. Mariona Graupera, from the Josep Carreras Leukaemia Research Institute and CIBERONC, have found the AKT inhibitor miransertib could be a new, effective molecular treatment ...
Jun 14, 2022
0
19
New research describes how highly proliferative leukemia cells end up becoming normal cells that no longer multiply, by changing the chemical modifications—the so-called epigenetics—of a type of its genetic material: ...
Jun 9, 2022
0
10
A team led by Dr. Manel Esteller, Director of the Josep Carreras Leukemia Research Institute, has improved the computational identification of potentially druggable gene amplifications in tumors, from epigenetic data. By ...
May 11, 2022
0
2
